🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. CYTARABINE, CYTARABINE, Liposomal Annamycin, 0.9% Sodium Chloride Injection, USP/Ph. Eur./BP/JP

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE

    Lacuna Pharma Pty Ltd

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  3. Camrelizumab

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 3 small molecule active

    2 trials

  4. Cannabidiol Oil

    Hospital Authority, Hong Kong

    Dementia, Vascular

    phase 3 small molecule active

    1 trial

  5. Capecitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  6. Capecitabine Accord 150 mg film-coated tablets, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Irinotecan Accord 20 mg/ml Solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Stage III colorectal cancer

    phase 3 small molecule active

    1 trial

  7. Capecitabine monotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  8. Capecitabine plus temozolamide

    Hospital Authority, Hong Kong

    Neuroendocrine Neoplasia's (NENs)

    phase 3 small molecule active

    1 trial

  9. Capecitabine(Aibin)

    The First People's Hospital of Lianyungang

    Stage III Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  10. Capox chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  11. Carbetocin Nasal Spray

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  12. Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial)

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  13. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DS-8201a

    Daiichi Sankyo

    HER2-expressing endometrial cancer (IHC 3+/2+)

    phase 3 small molecule active

    1 trial

  14. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ribozar 1 g Pulver zur Herstellung einer Infusionslösung, Datopotamab deruxtecan, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  15. Cardioblate® Surgical Ablation System

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatic Valve Disease

    phase 3 other active

    1 trial

  16. Carrellizumab + Capecitabine

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  17. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial

  18. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent β-thalassemia (TDT)

    phase 3 small molecule active

    1 trial

  19. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-Dependent-Thalassemia

    phase 3 small molecule active

    1 trial

  20. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  21. Casodex 50 mg Film-coated Tablets, Zoladex 10,8 mg implantat

    Lacuna Pharma Pty Ltd

    Metastatic hormone-sensitive prostate cancer with high tumor load

    phase 3 small molecule active

    1 trial

  22. Casodex® 50 mg Film-coated Tablets, ANANDRON 150 mg, comprimé, Flutamide 250 mg Tablets, Xtandi - 40 mg soft capsules

    Ningbo Cancer Hospital

    Localised prostate cancer at high risk of recurrence

    phase 3 small molecule active

    1 trial

  23. Celestone Cronodose suspensión inyectable, Ropivacaína Altan 7,5 mg/ml solución inyectable EFG, PLATELET CONCENTRATE

    The George Institute

    CHRONIC OMALGIA

    phase 3 small molecule active

    1 trial

  24. CellCept 500 mg film-coated tablets, CellCept 1 g/5 ml powder for oral suspension, Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 500 mg film-coated tablets

    Hoffmann-La Roche

    Childhood Idiopathic Nephrotic Syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources